If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
341
results.
Updated on
15/11/2026 [08:23:00]
Absstract of: DE102025117473A1
Die Erfindung betrifft ein Verfahren für die Diagnose einer neurodegenerativen Krankheit eines Individuums, bei dem in-vitro in einer biologischen Probe des Individuums eine für die Diagnose der neurodegenerativen Krankheit charakteristische Expression eines Proteins mittels einer Analyse eines für die Expression des Proteins spezifischen Biomarkers bestimmt wird.Die Erfindung zeichnet sich dadurch aus, dass das Protein ausgewählt ist aus HMG-CoA Synthase, SERPINA3, Pyruvat-Carboxylase, SCP-2, Myosin light polypeptide 6 und/oder Heat shock protein 60.Die Erfindung betrifft zudem zwei pharmazeutische Erzeugnisse sowie ein Kit und eine Verwendung.
Absstract of: US20260358352A1
The invention relates to identification of an intron-retaining Tau splicing isoform as a novel Alzheimer's disease biomarker. Provided herein are polypeptides to generate binding molecules, such as antibodies specific for the Tau11i isoform, oligonucleotides and antibodies for use in methods for detecting the Tau11i isoform in a sample and methods for use in diagnosis for Alzheimer's disease.
Absstract of: US20260358353A1
Provided is a protein marker Nell-1, which is present in a person's blood sample in an amount that is correlated with neurodegenerative disorders such as Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI), and Parkinson's Disease (PD). Corresponding diagnostic and treatment methods for these neurodegenerative disorders as well as kits for diagnosing or treating the neurodegenerative disorders are also provided.
Absstract of: US20260358355A1
Tools for identifying risk of and for treating vascular contributions to cognitive impairment and dementia (VCID) and stroke-induced cognitive impairment in a subject are provided and include a method and a device that involve detecting target proteins in systemic blood sample from the subject.
Absstract of: US20260358351A1
A use of a new highly toxic amyloid oligomer Aβo*3F as a target for diagnosing Alzheimer's disease (AD) in the early stage and the middle-late stage and mild cognitive impairment (MCI) caused by AD. The Aβo*3F specifically binds to a antibody 3F and is present in cerebrospinal fluid (CSF), blood and/or brain tissue of AD patients and patients with MCI caused by AD, and the levels show highly significant differences in CSF, blood and/or brain tissue of AD patients, MCI patients and healthy elderly persons. In addition, the Aβo*3F is an ultra-highly toxic oligomer, is the most important toxic component in an Aβ oligomer mixture, has a strong pathogenic effect, and plays a key role in the occurrence and development of AD.
Absstract of: EP4837918A1
The present invention relates to a surface-functionalized optical element comprising an IR-transparent optical element, wherein at least a part of the surface of the IR-transparent optical element is surface-functionalized, wherein said surface functionalization comprises a surface attachment moiety covalently attached to the surface of the IR-transparent optical element, and wherein at least part of the surface attachment moieties is covalently attached to a spacer moiety comprising a poly(alkylene oxide), wherein at least part of the spacer moieties is covalently attached to a charge optimization moiety, wherein said charge optimization moiety comprises a functional group that is charged under conditions of use of the optical element and optionally a poly(alkylene oxide), wherein at least part of the charge optimization moiety is covalently attached to a linker moiety comprising a poly(alkylene oxide), wherein at least part of the linker moieties is covalently attached to a molecular probe. The invention further relates to a single chain variable fragment (scFv) that can be used as a molecular probe for the capture of alpha-synuclein as well as sensor elements and sensors comprising said surface-functionalized optical element and/or scFv, and methods and uses thereof.
Absstract of: EP4838226A1
0001 A method of quantifying plasmalogen includes: a measurement sample preparation step of mixing a specimen containing protein and plasmalogen with Schiff reagent, to obtain a measurement sample; a control sample preparation step of mixing the specimen with a solvent of the Schiff reagent, to obtain a control sample; a measurement step of measuring a degree of a first optical property of the measurement sample after reaction of the Schiff reagent with an aldehyde generated from a vinyl ether bond of the plasmalogen, and a degree of an optical property of the control sample; and a determination step of determining a plasmalogen concentration in the specimen by comparing a corrected degree obtained by correcting the degree of the first optical property with the degree of the optical property of the control sample, with a degree of a second optical property of a standard sample containing Schiff reagent and plasmalogen having a known concentration, the degree of the second optical property being obtained after reaction of the Schiff reagent with an aldehyde generated from a vinyl ether bond of the plasmalogen.
Absstract of: WO2026231884A1
The present disclosure provides a method of determining the presence and/or the quantity of a target in a sample and a method of determining the presence and/or the quantity of single nucleotide polymorphisms (SNPs) in a nucleic acid sample.
Absstract of: WO2026231288A1
A method for diagnosing an injury in a patient who was exposed to a blast includes obtaining a sample from the subject and extracting miRNA from the sample. The method further includes determining the miRNA in the sample. Finally, the method includes diagnosing a patient's injury based on the miRNA present in the sample.
Absstract of: WO2026231974A1
Provided herein are methods and systems for noninvasive disease detection using high resolution microbiome profiling. Also provided are disease-associated bacterial and fungal sequence features used to detect, classify, or assess risk of diseases associated with microbiome dysbiosis.
Absstract of: WO2026231940A1
The present disclosure relates to compositions comprising a sterile, stable leukapheresis product comprising nonexpanded populations of cells derived from peripheral blood via a leukapheresis procedure, wherein the leukapheresis product comprises one or more subpopulations of cells including T cells, B cells, NK cells, monocytes, macrophages, neutrophils, eosinophils, basophils, or mast cells, and wherein the leukapheresis product reliably, reproducibly and consistently preserves the quality, composition, and characteristics of the nonexpanded populations of cells and the subpopulations are preserved from batch to batch and from aliquot to aliquot within the batch. The present disclosure also relates to methods of preparing the sterile, stable leukapheresis product.
Absstract of: JP2026176820A
【課題】新規バイオマーカーを用いた多系統萎縮症の検査を補助するための情報を提供することを課題とする。【解決手段】多系統萎縮症の検査を補助するための情報を提供する情報提供方法であって、該情報提供方法は、被検者から採取した脳脊髄液に含まれる、キノリン酸および／またはキヌレン酸の含有量を測定する測定工程と、前記測定工程で得られたキノリン酸および／またはキヌレン酸の含有量の情報を提供する情報提供工程と、を含む情報提供方法。【選択図】図２
Absstract of: WO2026229603A1
Provided herein are methods of quantifying the concentration of a target polypeptide in a test sample. Also provided are associated further methods and kits.
Absstract of: WO2026232103A1
Provided herein are a biocomputing system. The biocomputing system includes at least two hybrid modules, each hybrid module comprising a communications array and a living specimen grown on the communications array. The communications array is configured to record and stimulate the living specimen and each of the hybrid modules is configured to communicate with at least one of another hybrid module or a computer. Also provided herein is a machine-learning assisted method of characterizing living tissue input-output transformations with a hybrid module.
Absstract of: WO2026229758A1
This disclosure describes methods and compositions for detecting the presence of a RIMKLA autoantibody in a biological sample. Also provided are methods of treating subjects with progressive neurologic dysfunction, a paraneoplastic neurological disorder and/or cancer.
Absstract of: WO2026231779A1
Disclosed herein are methods for determining a risk of developing autism spectrum disorder (ASD) in newborns.
Absstract of: WO2026231697A1
Described herein are methods of using a nanobiosensor to quantitatively measure expression of one or more genes associate with cognitive function in live cells. The methods include comparing the level of expression of the one or more gene associated with cognitive function to a library of gene expression levels to aide medical practitioners in determining the level of cognitive function and cause of cognitive decline in a patient.
Absstract of: US20260347440A1
0000 The present disclosure provides monoclonal antibodies, and method of use thereof, for diagnosing and/or treating P. gingivalis infection and/or chronic diseases resulted from or associated with such infection. Specific antigen-antibody reaction regions on each P. gingivalis outer membrane protein are also identified and used for developing vaccines for prevention and treatment. The monoclonal antibodies of the present disclosure cross-react with different antigen regions of different P. gingivalis outer membrane protein. Animal models and diagnostic kits for serological evaluation and assessment of prognosis and treatment effectiveness after P. gingivalis infection are also provided.
Absstract of: US20260345604A1
The disclosure relates to lemborexant, a dual orexin receptor antagonist, and compositions and methods for use in treatment of Alzheimer's disease (AD), e.g., in a subject who has AD or who is at risk for developing AD.
Absstract of: WO2026230961A1
One embodiment of the present invention relates to: a marker composition for neurological diseases in a subject, comprising neurofilament light chain (NfL) and osteopontin (OPN) proteins or genes encoding the proteins; a diagnostic composition; a kit; and a method for providing information. The present inventors have identified that neuronal degeneration can be detected early, disease progression can be predicted, and a customized treatment strategy can be established using neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and osteopontin (OPN) biomarkers. In addition, it has been demonstrated that by applying multi-biomarker analysis, complex pathological mechanisms of neurodegenerative diseases can be more accurately reflected and diagnostic accuracy and sensitivity higher than those of a single biomarker can be ensured. Therefore, the multi-biomarker-based analysis method according to the present invention can be used as a useful tool for early diagnosis of neurodegenerative diseases, monitoring of disease progression, and evaluation of treatment response.
Absstract of: WO2026230519A1
The present invention pertains to an Aquaporin-4 (AQP4) expression enhancer containing, as an active ingredient, naltrexone (CAS number: 16590-41-3) or a pharmaceutically acceptable salt thereof. The expression enhancer is useful for applications in maintaining or improving physiology functions involved in, suppressing progression of, and reducing the onset risk of, conditions related to hypofunction of the glymphatic system through regulation of expression of AQP4. The present invention also provides a screening method for selection of a substance useful for conditions related to hypofunction of the glymphatic system, by using, as an index, the expression level of AQP4 using human-derived astrocytes.
Absstract of: US20260348983A1
The purpose of the present technology is to provide a technique for accurately determining cognitive impairment, cognitive decline, or risk of any of them. The present technology provides a determination supporting information generating method, that includes the steps: an index value calculating step of calculating, based on amounts of two or more biomarkers contained in a biological sample derived from a human, (I) a first index value indicating the presence or absence of cognitive impairment or cognitive decline in the human and (II) a second index value indicating the degree of progression of cognitive impairment or cognitive decline in the human; and a supporting information generating step of generating information that supports determination of cognitive impairment, cognitive decline, or risk of any of them, based on the first index value and the second index value.
Absstract of: US20260347408A1
The present invention relates to a peptide capable of directly binding to amyloid beta protein Aβ42, known to be a causative agent of Alzheimer's disease, and a composition for treating and preventing Alzheimer's disease, comprising the peptide. The peptide of the present invention can be used to prevent fibrosis and oligomerization of amyloid beta, and thus can be used for the treatment and prevention of amyloidogenic disease such as Alzheimer's disease. In addition, the peptide of the present invention can be used to detect amyloid beta, and thus can be used for the diagnosis of amyloidogenic diseases such as Alzheimer's disease.
Absstract of: US20260347407A1
The present invention relates to a peptide capable of directly binding to amyloid beta protein Aβ42, which is known to be a causative agent of Alzheimer's disease, and a composition for the treatment and prevention of Alzheimer's disease, comprising the peptide. When peptide SMA_04088-2 of the present invention is used, the fibrilization and oligomerization of amyloid beta can be prevented, and thus, the peptide SMA_04088-2 can be used in the treatment and prevention of amyloid diseases such as Alzheimer's disease. In addition, the peptide SMA_04088-2 can be used to detect amyloid beta, and thus can be used in the diagnosis of amyloid diseases such as Alzheimer's disease.
Nº publicación: US20260347771A1 05/11/2026
Applicant:
UNIV OF WASHINGTON [US]
UNIVERSITY OF WASHINGTON
Absstract of: US20260347771A1
0000 The technology described herein is directed to compositions and methods for establishing salivary gland organoid culture. Such salivary gland organoid cultures are derived in vitro from pluripotent stem cells, such as induced pluripotent stems. Also described herein are uses for the salivary gland organoid cultures, including as a model for a salivary gland-associated disease or to screen for an effective therapeutic for a salivary gland-associated disease.
BOPI
Electronic site
